High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation
Autor: | Alex Crowe, Edward G. Hyde, Virginia M.-Y. Lee, Carlo Ballatore, John Q. Trojanowski |
---|---|
Rok vydání: | 2007 |
Předmět: |
Reducing agent
High-throughput screening Drug Evaluation Preclinical Biophysics tau Proteins macromolecular substances Biochemistry Fluorescence Article Dithiothreitol law.invention Structure-Activity Relationship chemistry.chemical_compound law Quinoxalines mental disorders medicine Structure–activity relationship Benzothiazoles Furans Molecular Biology Fluorescent Dyes Heparin Drug discovery Neurofibrillary Tangles Cell Biology Small molecule Recombinant Proteins Thiazoles chemistry Recombinant DNA medicine.drug |
Zdroj: | Biochemical and Biophysical Research Communications. 358:1-6 |
ISSN: | 0006-291X |
DOI: | 10.1016/j.bbrc.2007.03.056 |
Popis: | A library of approximately 51,000 compounds was interrogated by high throughput screening (HTS) using a heparin-induced tau fibrillization assay. HTS was conducted with bacterially expressed recombinant tau fragment K18 and the reaction was monitored by thioflavine T fluorescence. Hits meeting criteria set for selection in HTS were further evaluated in a panel of assays designed (a) to confirm the initial results and (b) to identify possible false positives arising from non-specific mechanisms or assay-dependent artifacts. Two 2,3-di(furan-2-yl)-quinoxalines were confirmed as inhibitors of tau fibrillization with IC(50)s in the low micromolar range (l-3 microM). Among false positive hits, members of the pyrimidotriazines, benzofurans, porphyrins, and anthraquinone, inhibited tau fibrillization by generating peroxides via catalytic redox cycles due to the reducing agent dithiothreitol (DTT) in the assay. This study delineates focused strategies for HTS of tau fibrillization inhibitors that are relevant to drug discovery for Alzheimer's disease and related tauopathies. |
Databáze: | OpenAIRE |
Externí odkaz: |